<DOC>
	<DOCNO>NCT02643082</DOCNO>
	<brief_summary>Study Evaluate Effects PT003 Placebo MDI Specific Image Based Airway Volumes Resistance With Moderate Severe COPD .</brief_summary>
	<brief_title>A Study Assess Effects PT003 Placebo MDI Specific Image Based Airway Volumes Resistance Subjects With Moderate Severe COPD</brief_title>
	<detailed_description>A Randomized , Double-Blind , Two Treatment , Two Period , Chronic Dosing ( 2 Weeks ) , Cross-Over , Single-Center Study Evaluate Effects PT003 Placebo MDI Specific Image Based Airway Volumes Resistance Subjects With Moderate Severe COPD .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Nonchild bear potential ( ie , physiologically incapable become pregnant , include female 2 year postmenopausal ) ; Child bear potential , negative urine pregnancy test Visit 1 agree acceptable method contraception Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoking . At Visit 1 , FEV1/FVC ratio must &lt; 0.70 At Visit 1 , postbronchodilator FEV1/FVC ratio &lt; 70 % FEV1 must 30 % 80 % predict normal value , calculate use NHANES III reference equation . Exclusion criterion : Significant disease COPD , i.e. , disease condition , opinion Investigator , may put subject risk participation study may influence either result study subject 's ability participate study . Women pregnant lactating , plan become pregnant course study , woman childbearing potential use acceptable method contraception . Subjects , opinion Investigator , current diagnosis asthma . Subjects hospitalize due poorly control COPD within 3 month prior Visit 1 ( Screening ) runin period ( Visit 1 Visit 2 ) . Subjects poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior Visit 1 ( Screening ) runin period ( Visit 1 Visit 2 ) . Subjects diagnosis angle closure glaucoma exclude , regardless whether treat . Subjects history hypersensitivity Î²2agonists , glycopyrronium muscarinic anticholinergic , component MDI . Please refer study protocol complete inclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>